Remove 2028 Remove FDA Approval Remove Licensing
article thumbnail

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

The Pharma Data

In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 This compares with licensing and royalty revenue of $0.2 1 (908) 892-2028 PR@amarincorp.com (media inquiries). . Licensing and royalty revenue. million and $8.9 million and $5.7 million and $1.1 million and $346.5

article thumbnail

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

The Pharma Data

. A follow-on procurement contract with HHS is expected for the delivery of raxibacumab, the Company’s Food and Drug Administration-approved anthrax monoclonal antibody therapeutic, to the Strategic National Stockpile (SNS). FOOTNOTES. (1)

article thumbnail

Flurpiridaz F 18

New Drug Approvals

3] Flurpiridaz ( 18 F) was approved for medical use in the United States in September 2024. [3] 3] Flurpiridaz ( 18 F) was approved for medical use in the United States in September 2024. [3] Food and Drug Administration (FDA). Food and Drug Administration (FDA). Flurpiridaz F 18 WeightAverage: 367.84 27 September 2024.

FDA 57